Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer

Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07674732 by Dechang Diao, with a registry enrolment figure of 76 participants, started 2026-06-24 and due to reach its primary completion in 2029-06-24. Interventions recorded: Short-course Radiotherapy plus Chemotherapy; Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab. Conditions listed: Short-course Radiotherapy Plus Chemotherapy; Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab. Primary outcome: Complete Response (CR) Rate; Adverse events. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.